TECLens treated the first patient in a first-in-human trial assessing safety and efficacy of qCXL-based refractive correction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results